Physician profile
Antonio E Hachem
NPI 1306844709
$3,191.37
in general payments reported to CMS, 2019-2025
14 companies · $670 in 2025
The $670 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $87.78 · 2021: $264 · 2022: $121 · 2023: $619 · 2024: $957 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $683.47 | 2019-2025 | Precision 1, Precision7, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $468.18 | 2019-2024 | Acuvue |
| Amgen INC. | $279.67 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $253.87 | 2020-2024 | |
| Dompe US, INC. | $243.99 | 2024-2025 | Oxervate |
| Abbvie INC. | $241.71 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $237.52 | 2023-2024 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $174.91 | 2019 | |
| Lkc Technologies, INC. | $132.24 | 2025 | |
| Harrow Eye, LLC | $121.93 | 2025 | Vevye |
| Coopervision INC. | $118.32 | 2022-2023 | Cvi Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.04 | 2019 | |
| Glaukos Corporation | $89.22 | 2024 | Ce-Marked Kxla System |
| Rxsight INC | $47.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Hachem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.